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Introduction 
Increment of antibiotic resistance and consumption is 
one of the most serious global threats to the treatment of 
infectious diseases [1, 2, 3, 4, 5]. In addition as a conse-
quence it results in significant increases in costs and toxic-
ity of newly appeared drugs, antibiotic resistance compli-
cates the quality of therapeutic treatment. Countries and 
hospitals with the fewest control in antibiotic prescribing 
have the greatest frequency of resistant organisms, [6] 
which suggests a causal connection and necessity of anti-
biotics consumption evaluation. In The United States, 160 
million antibiotic prescriptions are written annually for 
humans; these figures equate to 30 prescriptions and 4.1 kg 
of antibiotics per 100 persons per year. Such industrialized 
nations as France, Australia, The United States, Canada, It-
aly and the United Kingdom have the highest rates of oral 
antimicrobial prescriptions, ranging from 33 to 16 defined 
daily doses per 1000 population per day [7, 8]. All around 
the world in hospitals the use of other beta-lactam anti-
bacterials recorded approximately 15-20%, while in EMI 
50-60% of all antibiotics consumption. That situation de-
termined higher attention for this group of anti-infectives 
for systemic use in medicine [9, 10, 11] including surveil-
lance, stringent use control and rational prescription, sup-
porting the importance of antimicrobial consumption on 
resistance 12].
The primary aim of the study was to evaluate institu-
tional representative data on other beta-lactam antibacteri-
als utilization, in accordance with the World Health Orga-
nization (WHO) requirements, directed to determine the 
value of Defined Daily Doses (DDD) per 1000 Occupied-
Bed Days (DDD/1000) and value cost in the dynamics per 
total institution and most important departments [13].
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Abstract
Background: The use of other beta-lactam antibacterials in the Emergency Medicine Institute (EMI) recorded in the medium 60%, while around 
the world in hospitals only 15-20% on average, from all yearly antibiotics consumption. That argument represents an important scientific and practical 
interest for evaluation of other beta-lactam antibacterials.
Material and methods: For this study we used the data of a six-year (2009-2014) period in the EMI and their subdivisions with main consumption 
of antibiotics which show dynamics of the use of other beta-lactam antibacterials in grams and value indexes.
Results: In EMI, during the evaluated period other beta-lactam antibacterials recorded a stable consumption (Defined Daily Doses, DDD) from 270.8 
to 272.6 DDD/1000 or 58.74% of the total in 2014, with an increase of 0.67% and a decrement in septic surgery and orthotrauma (SSOT) departments 
from 238.6 to 231.54 DDD/1000 or by 2.96%. A sharp decrease registered in intensive care (IC) departments from 1416.54 to 636.78 DDD/1000 or by 
55.05%. In the end of the evaluated period IC departments recorded 24861.5 lei per DDD/1000 that was 7.18 times more than the cost of 3460.46 lei 
registered in SSOT departments and respectively 4.53 times higher than the cost of 5489.7 lei recorded per DDD/1000 in the entire EMI. 
Conclusions: We find that in the evaluated period in EMI, the consumption of other beta-lactam antibacterials recorded in medium the similar 
yearly data, while the same data in some European and Australian hospitals are on average respectively by 2.18 and 1.32 times less. 
Key words: other beta-lactam antibacterials, defined daily dose, consumption, rational use, hospitals.
Material and methods
For this study we used the data of a six-year (2010-
2014) period DDD/1000 consumption of other beta-lac-
tam and penicillin antibiotics in EMI (Emergency Medi-
cine Institute) and their main subdivisions intensive care 
departments (ICD – reanimation, intensive therapy and 
intensive neurological “stroke” departments) and SSOTD 
(septic surgical and septic orthotraumatology depart-
ments) [14] which show the dynamics of consumption 
of anti-infectives for systemic use drugs as classified by 
Anatomical Therapeutic Chemical (ATC) classification 
system of World Health Organization (WHO) indicated in 
grams and value indexes. Statistical, analytical, mathemati-
cal, comparative, logical and descriptive were used as the 
methods of study.
Results and discussion
For determining the number of DDD/1000 we used data 
about total annual consumption of other beta-lactam anti-
bacterials and the statistics data concerning the number of 
treated patients (only patients with health insurance and 
other free treated by the state categories of citizens). The 
total number of occupied bed/days in the institution was 
188762 in 2009, 191556 in 2010, 186246 in 2011, 199816 in 
2012, 193019 in 2013 and 187558 in 2014 and respectively 
for the evaluated departments of EMI: reanimation depart-
ment (2009 = 3990; 2010 = 6551; 2011 = 6985; 2012 = 9051; 
2013 = 7384;  2014 = 7361),  intensive therapy department 
(2010 = 2922; 2011 = 3327; 2012 = 3239; 2013 = 3407; 2014 
= 3388), intensive neurological “stroke”  department (2013 
= 2553; 2014 = 4193), septic surgical department (2009 = 
14030; 2010 = 14212; 2011 = 12875; 2012 = 12372; 2013 = 
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12464; 2014 = 12104),  septic  orthotraumatology  depart-
ment (2009 =10664; 2010 = 10017; 2011 = 9540; 2012 = 
10178; 2013 = 9701; 2014 = 9535) [15, 16, 17, 18].
Consumption of other beta-lactam antibacterials in 
EMI  is characterized by the use of parenteral (P) and en-
teral (E) forms of many subgroups with the respective no-
menclature of antibiotics as following: the first-generation 
of cephalosporins (Cefalexinum DDD 2.0E, Cefazolinum 
DDD 3.0P), the second-generation of cephalosporins (Ce-
furoximum DDD 0.5E, 3.0P, Cefaclorum DDD 1.0E), the 
third-generation of cephalosporins (Cefotaximum DDD 
4.0P, Ceftazidimum DDD 4.0P, Ceftriaxonum 2.0P, cefixim 
DDD 0.4E, Cefoperazonum DDD 4.0P, Cefoperazonum 
+ culbactamum DDD 4.0P) and carbapenems (Meropen-
emum DDD 2.0P, Imipenemum+cilastatinum DDD 2.0P). 
Total other beta-lactam antibacterials consumption in 
DDD/1000 during 2009-2014 is shown in figure 1.
From figure 1, it could be observed a total decrease of 
other beta-lactam antibacterials consumption for all de-
partments. According to the annual medium consumption 
of all departments of 2701.58 DDD/1000 could be placed 
as following: first – reanimation department with  970.38 
DDD/1000 or 35.92% and a decrease from 1416.54 to 
886.7 DDD/1000 or by 37.34%, second –  intensive therapy 
department with 794.95 DDD/1000 or 29.43% and a de-
crease from 974.67 in 2010 to 597.7 or by 38.68%, third 
- intensive neurological «stroke» department with 467.76 
DDD/1000 or 17.31% and a decrease from 509.6 in 2013 
to 425.95 or by 16.42%, fourth - septic surgical department 
with 237.92 DDD/1000 or 8.81% and a decrease from 
310.05 to 187 DDD/1000 and septic  orthotraumatology 
department with  230.57 DDD/1000 or 8.53% and an in-
crease from 167.1 to 276.14 DDD/1000 or by 65.25% on 
the position number five. In figure 2 the total other beta-
lactam antibacterials consumption of parenteral forms in 
DDD/1000 during 2010-2014 is shown.
In figure 2 parenteral forms of other beta-lactam an-
tibacterials consumption is presented. As it could be ob-
served from figure 1 and 2 the consumption of parenteral 
forms of other beta-lactam antibacterials in the mean are 
similar with the total results.
In figure 3 totals DDD/1000 of other beta-lactam anti-
bacterials (enteral forms) consumption during 2009-2014 
are shown.
The data from figure 3 shows that in the evaluated 
period enteral forms of other beta-lactam antibacteri-
als recorded a significant increament from 0.93 to 61.25 
DDD/1000 or by 65.86 times in septic orthotraumatology 
department and from 2.75 to 10.08 DDD/1000 or by 3.67 
times in septic surgical department. Other departments 
Fig. 1.  Total other beta-lactam antibacterials consumption in DDD/1000 during 2009–2014.
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registered an occasional or didn’t record any consumption 
of this group of antibiotics.
Taking into consideration the situation that in most 
scientific journals the published data about drugs con-
sumption include the use of them in all intense care hos-
pital unites, we determined the medium consumption of 
DDD/1000 separately for ICD and SSOTD (septic surgi-
cal and septic orthotraumatology departments) of EMI. 
To determine the medium consumption of DDD/1000 we 
counted total of DDD/1000 separately for ICD and SSOTD 
and divided by the number of those departments (3 and 
respectively 2). The results are shown in table 1.
The data in table 1 shows that in the evaluated period 
total consumption in ICD departaments of other beta-
lactam antibacterials decreased from 1416.54 to 636.8 
DDD/1000 or by 55.05% and respectively in SSOTD from 
238.9 to 231.54 DDD/1000 or by 3.08%. Consumption in 
ICD departments in 2014 was by 2.75 (636.8:231.54) times 
more than in SSOTD departments. Total institutional 
parenteral forms recorded a decrease from 268.6 to 239.3 
DDD/1000 or by 10.91% and vice versa enteral forms a 
significant increase from 2.2 to 25.3 DDD/1000 or by 11.5 
times. In table 2 total records of parenteral and enteral 
forms consumption in EMI are shown.
From table 2 it could be observed that during the evalu-
ated period other beta-lactam antibacterials in EMI record-
ed a stable consumption from 270.8 to 272.6 DDD/1000 
with an increase of 0.67% that in 2014 represents a share of 
58.74% of the total. In large acute international public hos-
pitals and other international hospitals, it was registered an 
increase from 191 to 206.31 DDD/1000 or by 7.91% that in 
2014 represented a share of 22.01% of the total of 936.31 
DDD/1000. In some hospitals of European countries 
consumption of this group of drugs recorded a decrease 
from 144.5 to 125 DDD/1000 or by 13.40% that in 2013 
represented a share of 17.60% from the total. In a Single 
University Hospital a medium consumption in the period 
from 2001 to 2012 recorded 348.2 DDD/1000 or a share of 
54% of the total 644.6 DDD/1000.  In French hospitals in 
2007 consumption represented 67.7 DDD/1000 or 12.14% 
from the total of 557.7 DDD/1000 in 27 public teaching 
hospitals, 36.3 DDD/1000 or 9.77% from the total of 371.5 
DDD/1000 in 165 non – teaching public hospitals and 67.3 
DDD/1000 or 16.14% from the total of 416.9 DDD/1000 in 
158 private hospitals [21].  The same data in 130 US hos-
pitals in 2002-2003 represented 80.3 DDD/1000 or 10.14% 
from total 792 DDD/1000 [22].
The value cost of other beta-lactam antibacterials use 
per DDD/1000 in lei is presented in figure 4.
As it could be seen from figure 4, during the evaluated 
Fig. 3.  Total other beta-lactam antibacterials consumption in DDD/1000 (enteral forms).
Table 1
Other beta-lactam antibacterials (parenteral and enteral forms) consumption in DDD/10
Department Administration 2009 2010 2011 2012 2013 2014
ICD
Parenteral 1416.54 868.73 871.39 812.51 765.97 636.8
Enteral     1.43   1.47  
Total 1416.54 868.73 872.1 812.51 766.33 636.78
SSOTD
Parenteral 236.76 326.54 151.47 207.8 212.54 195.87
Enteral 1.84 0.71 10.25 7.22 18.81 35.67
Total 238.6 327.25 161.72 215.02 231.35 231.54
Total  EMI
Parenteral 268.6 257.6 256.1 213 256.6 239.3
Enteral 2.2 3.6 16.7 12.4 14.1 25.3
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period the main value cost of DDD/1000 recorded reani-
mation department from 40128.3 lei to 33981.3 lei or a de-
crease by 15.32%, consequently the second position holds 
intensive therapy department from 35143.5 lei in 2010 to 
29271.2 lei or a decrease by 16.71% and thirdly the inten-
sive neurological «stroke» department from 11695 lei in 
2013 to 11332 lei or a decrease by 3.10%, followed by  sep-
tic surgical department from 5495.4 lei to 3330.55 lei or a 
decrease by 39.39% and the last position was held by septic 
orthotraumatology  department from 3177.24 to 3590.36 
lei or an increment by 13%.
In figure 5 the total value cost of other beta-lactam an-
tibacterials in DDD/1000 (parenteral forms) is presented.
The cost of parenteral other beta-lactam antibacterials 
in DDD/1000 for all departments remains approximately 
the same comparatively with the total consumption be-
cause of low cost of enteral forms for DDD/1000. In figure 
6 the value cost of DDD/1000 in lei of other beta-lactam 
antibacterials enteral forms is shown.
Presented data in chart 6 demonstrates that from the 
total departments annual costs could be placed as follow-
ing: the first septic orthotraumatology department with 
the cost per DDD/1000 from 3.02 lei to 329.52 lei and the 
second septic surgical department with the cost from 46.73 
lei to 72.45 lei per DDD/1000. Other departments because 
of the lack or very low consumption didn’t record at all, or 
recorded an episodic price per DDD/1000.
To determine the medium cost of DDD/1000 of other 
beta-lactam antibacterials was counted the total cost of 
DDD/1000 separately for ICD and SSOTD and divided by 
the number of those departments (3 and respectively 2).
As it could be seen from table 3 in the evaluated period 
total medium cost of DDD/1000 for other beta-lactam an-
tibacterials recorded a decrease in ICD departments from 
40128.3 lei to 24861.5 lei or by 38.05% and consequently, 
in SSOTD from 4336.32 lei to 3460.46 lei or by 20.20%. 
Medium cost of DDD/1000 in SSOTD departments was 
less than in ICD departments by 8.21 times in 2009 and re-
Table 2
Other beta-lactam antibacterials consumption of DDD/1000 in EMI and some international hospitals
 Programs/institutions 2009 2010 2011 2012 2013 2014
Emergency Medicine Institute 270.8 261.2 272.7 225.6 270.7 272.6
Total 662.4 558.2 622.1 542.4 546.9 464.1
Percentage 40.88% 46.79% 43.84% 41.59% 49.5% 58.74%
Large acute Australian pub. hospitals [19] 191 193.1 222 178.4 186.9 206.11
Total 931.8 933.7 946.5 931.6 943.4 936.31
Percentage 20.49% 20.68% 23.45% 19.15% 19.77 22.01%
2012 2001 - 2012 - 2013 2013
Single University Hospital [20] 348.2
NAUSP;   SAAUSP [19] 203;186
DANMAP; SWEDRES; NETHMAP (192+97):2=144.5 125
Total ( 931+609):2=770 631;945;943 712
Percentage 18.77% 55%;27%; 22%;29% 17.6%
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Fig. 5.  Value cost of other beta-lactam antibacterials in DDD/1000 of parenteral forms in lei.
Table 3
Medium cost of DDD/1000 in lei of other beta-lactam antibacterials (parenteral and enteral forms) in EMI
Department Structure of consumption 2009 2010 2011 2012 2013 2014
ICD
Parenteral 40128.3 30354.97 22060.76 26212.93 25760.17 24861.52
Enteral   1.43  5.83  
Total 40128.3 30355 22062.2 26212.9 25762.1 24861.5
SSOTD
Parenteral 4311.445 7541.72 4194 2794.39 2290.455 3259.47
Enteral 24.88 14.31 30.27 67.29 137.86 200.99
Total 4336.32 7556.03 4224.27 2861.68 4259.34 3460.46
Total  EMI
Parenteral 4888.31 5873.17 4942.22 4473.53 5278.44 5368.52
Enteral 17.18 26.03 103.44 136.74 205.86 121.19
Total  4905.49 5899.2 5045.66 4610.27 5484.3 5489.7
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spectively by 7.18 times in 2014. At the same time, the total 
institutional cost of DDD/1000 increased from 4905.49 in 
2009 to 5489.7 DDD/1000 in 2014 or by 11.91% and was 
less than medium cost in ICD departments by 4.53 times.
Conclusions
1. In EMI, during the evaluated period the use of other 
beta-lactam antibacterials recorded a stable consumption 
in a medium of 272 DDD/1000 in comparison with 125 
DDD/1000 in some European hospitals as all as of 206.31 
DDD/1000 in Australian acute public hospitals or respec-
tively by 2.18 and 1.32 times less. 
2. As to the annual medium consumption of 2701.58 
DDD/1000 of all departments places are distributed as fol-
lowing: the first – reanimation department with 970.38 
DDD/1000 or 35.92%, the second – intensive therapy 
department with 794.95 DDD/1000 or 29.43, the third –
intensive neurological “stroke” department with 467.76 
DDD/1000 or 17.31%, the fourth – septic surgical depart-
ment with 237.92 DDD/1000 or 8.81% and a decrease from 
310.05 to 187 DDD/1000 and septic orthotraumatology 
department with  230.57 DDD/1000 or 8.53% on the fifth 
position.
3. Total consumption in ICD departamentals of other 
beta-lactam antibacterials decreased from 1416.54 to 636.8 
DDD/1000 or by 55.05% and respectively in SSOTD from 
238.9 to 231.54 DDD/1000 or by only 3.08%. Consump-
tion in ICD departments in 2014 was 2.75 times more than 
in SSOTD departments. 
4. Total medium cost of DDD/1000 for other beta-lac-
tam antibacterials recorded a decrease in ICD departments 
from 40128.3 to 24861.5 lei or by 38.05% and consequently 
in SSOTD from 4336.32 to 3460.46 or by 20.20%. At the 
same time, the total institutional cost of DDD/1000 in-
creased from 4905.49 in 2009 to 5489.7 DDD/1000 in 2014 
or by 11.91% and was less than  medium cost in ICD de-
partments by 4.53 times.
5. The findings of this study could serve a significant 
support for hospitals to compare the data concerning an-
timycotics consumption with the international health care 
institutions and to optimize in planning necessities as well 
as to improve rational use of other beta-lactam antibac-
terials.
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